👪

Inheritance

1

Autosomal recessive HP:0000007

USH4 segregates as an autosomal recessive trait. Affected individuals are homozygous or compound heterozygous for ARSG variants; the first-described families carried a homozygous founder allele and were consanguineous or from a genetically isolated population.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:33300174 SUPPORT Human Clinical

"we identified three novel pathogenic variants in ARSG, which segregated recessively with the disease in two families from Portugal"

States recessive segregation of ARSG variants in two independent families.

?

Discussions and Knowledge Gaps

2

Why does the same enzymatic block produce generalised lysosomal storage with neurodegeneration in mouse and dog, but disease confined to retina and cochlea in humans - even for carriers of the identical p.R99H allele?

HUMAN MODEL MISMATCH mismatch_arsg_species_divergence

Attached to

pathophysiology#Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate

This is not the usual model-fidelity caveat, where a model shows a milder or partial version of the human disease. Here the models show a substantially different and in some respects more severe disease, and the discrepancy is anchored at the level of a single shared variant. A human homozygous for p.R99H was neurologically intact at 74 while dogs homozygous for the same substitution lose the ability to stand. Any explanation has to account for that: candidate reasons include species differences in heparan sulfate 3-O-sulfation load, redundancy from another sulfatase in humans, lifespan and cell-turnover differences, or simply that the human neurological phenotype is subclinical - the two reported patients with mild cerebellar atrophy but no ataxia are the only hint of the latter. Which is true determines whether human USH4 should be watched for late neurological decline, and whether the mouse and dog can serve as preclinical models for a therapy aimed at the human disease.

Proposed experiments

Systematic neurological and cerebellar imaging of an ARSG cohort

exp_arsg_neuroimaging_cohort

Prospectively image the cerebellum and perform standardised neurological examination across the reported ARSG cohort, stratified by age and genotype. Two patients with mild cerebellar atrophy without ataxia have been noted incidentally; only systematic assessment can establish whether subclinical cerebellar involvement is the rule and simply never reaches the threshold that ataxia in dogs does.

Cross-species quantification of 3-O-sulfated heparan sulfate substrate load

exp_arsg_substrate_load_comparison

Measure 3-O-sulfated heparan sulfate content and the activity of the other eight enzymes of the pathway in matched human, canine and murine tissues. If human neural tissue simply presents less of the ARSG-dependent substrate, or has greater redundancy at that step, the species divergence would be explained without invoking a difference in the enzyme itself.

Should human ARSG deficiency be classified as Usher syndrome type 4, as a thirteenth mucopolysaccharidosis (MPS IIIE), or as both?

CONTROVERSY controversy_mps_iiie_versus_usher_iv

Attached to

pathophysiology#Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate

ARSG is unambiguously a lysosomal sulfatase acting in heparan sulfate degradation, which is the definitional criterion for a mucopolysaccharidosis, and the animal models store glycosaminoglycan exactly as an MPS should. Against that, the human phenotype has none of the somatic hallmarks of an MPS - no coarse facies, no dysostosis multiplex, no organomegaly - and human GAG accumulation has not been demonstrated. The disease was therefore named for what it looks like clinically rather than for the pathway it disrupts. This entry curates it as USH4, following MONDO and OMIM, while recording that the classification is contested rather than settled; the practical stake is whether these patients should be enrolled in MPS natural-history studies and offered MPS-directed therapies.

Proposed experiments

Direct assessment of glycosaminoglycan storage in ARSG-deficient humans

exp_human_gag_storage_assessment

Measure urinary and tissue glycosaminoglycans, and specifically 3-O-sulfated heparan sulfate species, in molecularly confirmed ARSG patients against matched controls. The MPS IIIE argument currently rests on the animal models plus the enzyme's known function; a direct negative result in humans would largely settle it, and a positive one would reopen the therapeutic question.

⚙

Pathophysiology

9

Biallelic ARSG Loss of Function

Homozygous or compound heterozygous variants in ARSG (hgnc:24102) are the initiating lesion. Reported alleles include missense changes affecting the catalytic site, nonsense and splice alleles. The founder allele in the first families, c.133G>T (p.D45Y), alters a fully conserved residue of the enzyme's catalytic site.

Downstream

Abolished Arylsulfatase G Sulfatase Activity

Failed Lysosomal Targeting with ER Retention

Show evidence (2 references)

PMID:29300381 SUPPORT Human Clinical

"We identified a homozygous founder missense variant, c.133G>T (p.D45Y) in arylsulfatase G (ARSG)"

Identifies the founding biallelic ARSG lesion.

PMID:29300381 SUPPORT In Vitro

"The identified variant affected a fully conserved amino acid that is part of the catalytic site of the enzyme."

Locates the founder variant in the catalytic site, explaining loss of activity.

Abolished Arylsulfatase G Sulfatase Activity

USH4 alleles tested functionally show complete loss of sulfatase activity, not a graded reduction. This has held across independently ascertained cohorts and across missense, nonsense and splice alleles, which is why the disease behaves as a clean enzyme-null state.

arylsulfatase G sulfatase activity GO:0008484 ⇓ LOSS OF FUNCTION

Downstream

Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate

Show evidence (3 references)

PMID:29300381 SUPPORT In Vitro

"Functional analysis of the wild-type and mutant proteins showed no basal activity of p.D45Y."

Direct demonstration that the founder allele abolishes enzyme activity.

PMID:39199020 SUPPORT In Vitro

"Functional experiments indicated the complete loss of sulfatase enzymatic activity upon ectopic expression of mutated ARSG cDNA."

Confirms complete loss of activity across a further set of nine subjects' alleles.

PMID:35226187 SUPPORT In Vitro

"Functional experiments indicated a loss of sulfatase activity of the mutant proteins."

Independent replication of the enzyme-null result in three unrelated subjects.

Failed Lysosomal Targeting with ER Retention

A second, parallel route to the same end point. Some pathogenic ARSG variants do not merely inactivate the enzyme in place - they prevent it reaching the lysosome at all, leaving the protein retained in the endoplasmic reticulum. Curated as its own node rather than folded into catalytic loss because it is a distinct molecular failure that would not be corrected by a strategy aimed only at restoring catalysis.

protein localization to lysosome GO:0061462 ↓ DECREASED

endoplasmic reticulum GO:0005783

Downstream

Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate

Show evidence (1 reference)

PMID:33300174 SUPPORT In Vitro

"these pathogenic variants abolish the sulfatase activity of the Arylsulfatase G enzyme and impede the appropriate lysosomal localization of the protein product, which appears to be retained in the endoplasmic reticulum"

Establishes mislocalization with ER retention as a mechanism accompanying catalytic loss for these alleles.

Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate

ARSG catalyses one obligate step in the nine-enzyme lysosomal heparan sulfate degradation pathway: removal of 3-O-sulfate from glucosamine. Losing it stalls the sequential catabolic chain at that residue. In mouse and dog this produces frank, generalised storage; in humans no generalised storage phenotype has been demonstrated, which is why the downstream node here is confined to the retina and cochlea.

heparan sulfate proteoglycan catabolic process GO:0030200 ↓ DECREASED

Animal models

Arsg knockout mouse Mouse partially recapitulates Reproduces the enzymatic block and demonstrates that it causes lysosomal heparan sulfate storage - but at a severity and tissue distribution never observed in human ARSG deficiency.

Downstream

RPE-Restricted ARSG Loss

Cochlear Sensory Dysfunction

Show evidence (2 references)

PMID:34405855 SUPPORT In Vitro

"Within this degradation pathway, Arylsulfatase G (ARSG) is critical for removing 3-O-sulfate from glucosamine, and mutations in ARSG are causative for Usher syndrome type IV."

Defines the precise enzymatic step ARSG performs and links its loss to USH4.

PMID:34405855 SUPPORT In Vitro

"The lysosomal degradation of heparan sulfate is mediated by the concerted action of nine different enzymes."

Establishes that ARSG acts within an obligate multi-enzyme sequential pathway.

RPE-Restricted ARSG Loss

In the retina, ARSG is not expressed where the disease is seen. In wild-type mouse retina the protein is detectable only in the retinal pigment epithelium, yet it is the photoreceptors that degenerate - so the photoreceptor loss is cell-non-autonomous, driven from the RPE. What the RPE does next is genuinely unresolved, and the two available species disagree. In Arsg-null mice the RPE is morphologically normal on electron microscopy and no storage vacuoles are found anywhere in the retina, which argues against a simple storage-crushes-the-RPE account. In ARSG-mutant dogs the RPE does accumulate autofluorescent storage bodies. The proposal that this perturbs the RPE-photoreceptor interactions required for photoreceptor maintenance is exactly that - the canine study states that the mechanism "remains to be elucidated". The node is therefore curated for what is established, the RPE-restricted site of action, with the downstream edge left as having unknown intermediates.

retinal pigment epithelial cell CL:0002586

Downstream

Photoreceptor Degeneration

Show evidence (3 references)

PMID:26975023 SUPPORT Model Organism

"Of note, expression of ARSG protein in wild-type mice was detectable only in the RPE which, however, appeared morphologically unaffected in knockout mice at the electron microscopic level."

Establishes both halves of this node: ARSG acts in the RPE rather than in photoreceptors, and the RPE nonetheless looks normal, so the mechanism is not simple RPE storage pathology.

PMID:26975023 SUPPORT Model Organism

"Electron microscopic analyses of retinas revealed no evidence for the presence of storage vacuoles."

Curated as PARTIAL because it is a negative finding that constrains the mechanism rather than supporting a positive one - it argues against storage-driven retinal degeneration in the mouse.

PMID:41295716 SUPPORT Model Organism

"the finding that the RPE of affected dogs accumulated autofluorescent storage bodies suggests that disease-related RPE pathology may alter the RPE–photoreceptor cell interactions that are necessary for maintaining normal photoreceptor cell functions"

The canine counterpart, curated as PARTIAL because the same paragraph states the mechanism remains to be elucidated and because canine RPE storage is not seen in the mouse.

Photoreceptor Degeneration

Rod and cone photoreceptors degenerate, producing a rod-cone dystrophy. The intermediate steps between stalled heparan sulfate catabolism and photoreceptor death are not established in human tissue, so the incoming edge is curated as having unknown intermediates.

retinal rod cell CL:0000604 retinal cone cell CL:0000573

Animal models

Arsg knockout mouse Mouse recapitulates Progressive, quantified photoreceptor loss with reactive gliosis - the arm of the human disease this model reproduces well, and the reason it is the reference model for USH4 retinal degeneration rather than for the mucopolysaccharidosis it is named after.

ARSG-mutant American Staffordshire Terrier Dog partially recapitulates Affected dogs showing ataxia had attenuated ERG amplitudes indicating rod and cone photoreceptor dysfunction, and autofluorescent inclusions were found in retinal pigment epithelium and ganglion cell layer.

Downstream

Pericentral and Macular Retinal Atrophy

Show evidence (1 reference)

PMID:39199020 SUPPORT Human Clinical

"This subtype was assigned as "USH IV" with a late onset of RP and usually late-onset progressive SNHL without vestibular involvement."

Establishes retinitis pigmentosa (rod-cone dystrophy) as the retinal phenotype of USH4.

Pericentral and Macular Retinal Atrophy

The distinctive structural lesion of USH4: ring-shaped atrophy running along the vascular arcades and encircling the fovea, giving a ring scotoma. The pattern is pericentral and macular rather than the mid-peripheral bone-spicule pattern of typical retinitis pigmentosa, and it is specific enough that it can suggest ARSG testing in an apparently isolated retinal dystrophy.

Downstream

Late-Onset Deaf-Blindness

Show evidence (2 references)

PMID:29300381 SUPPORT Human Clinical

"All patients shared a distinctive retinal phenotype with ring-shaped atrophy along the arcades engirdling the fovea, resulting in ring scotoma."

Describes the characteristic retinal lesion in all five founding patients.

PMID:35226187 SUPPORT Human Clinical

"This distinct type of USH is characterized by late-onset RP with predominantly pericentral and macular changes, and late onset SNHL without vestibular dysfunction."

Independent confirmation of the pericentral/macular distribution.

Cochlear Sensory Dysfunction

Progressive sensorineural hearing loss develops, typically after the retinal disease and usually in the fifth decade or later. Vestibular function is preserved - the labyrinth is spared even though the cochlea is not. No human cochlear histopathology is available for USH4, so the cell-type annotation below is the expected sensory target rather than a demonstrated site of injury.

cochlear inner hair cell CL:0000589

Downstream

Late-Onset Deaf-Blindness

Show evidence (1 reference)

PMID:29300381 SUPPORT Human Clinical

"In addition, patients developed moderate to severe sensorineural hearing loss."

Establishes sensorineural hearing loss in the founding cohort.

Late-Onset Deaf-Blindness

The combined sensory endpoint. What distinguishes USH4 from every other Usher type is when it arrives: both the visual and the auditory loss begin around the fourth decade, rather than in the first or second as in types 1-3. A patient can therefore complete education and working life before either deficit declares itself.

Animal models

ARSG-mutant American Staffordshire Terrier Dog fails to recapitulate The canine disease is dominated by progressive ataxia and cerebellar degeneration. The human disease has essentially no neurological component, and the defining human endpoint - combined late-onset visual and auditory loss - is not what the dogs present with.

Show evidence (2 references)

PMID:29300381 SUPPORT Human Clinical

"Both vision and hearing loss appeared around the age of 40 years."

Establishes the late, near-simultaneous onset that defines the subtype.

PMID:33300174 SUPPORT Human Clinical

"The probands were affected with retinitis pigmentosa and sensorineural hearing loss, generally with an onset of symptoms in their fourth decade of life."

Independent replication of fourth-decade onset in Portuguese families.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

6

Eye 3

Rod-Cone Dystrophy HP:0000510

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:41295716 SUPPORT Human Clinical

"Most of these patients display hearing loss and rod-cone dystrophy."

States rod-cone dystrophy as the dominant retinal phenotype across reported ARSG cases.

Nyctalopia HP:0000662

Show evidence (1 reference)

PMID:41295716 SUPPORT Human Clinical

"The homozygous p.R99H patient reported night blindness and photophobia starting in his early 40s and progressive hearing loss starting in his 50s."

Documents night blindness with age of onset in a confirmed ARSG homozygote.

Photophobia HP:0000613

Show evidence (1 reference)

PMID:41295716 SUPPORT Human Clinical

"The homozygous p.R99H patient reported night blindness and photophobia starting in his early 40s and progressive hearing loss starting in his 50s."

Documents photophobia in a confirmed ARSG homozygote.

Other 3

Pericentral Retinitis Pigmentosa HP:0007947

Show evidence (1 reference)

PMID:35226187 SUPPORT Human Clinical

"This distinct type of USH is characterized by late-onset RP with predominantly pericentral and macular changes, and late onset SNHL without vestibular dysfunction."

Directly states the pericentral and macular distribution of the retinopathy.

Bone Spicule Pigmentation Spicular pigmentation of the retina HP:0007737

Show evidence (1 reference)

PMID:35226187 SUPPORT Human Clinical

"The retinal phenotype is characterized by a specific distribution of atrophy around the arcades, peripherally surrounded by intraretinal bone spicules best appreciated nasally and superior to the disc."

Describes the bone spicule pigmentation and its characteristic distribution.

Progressive Sensorineural Hearing Impairment HP:0000408

Show evidence (1 reference)

PMID:39199020 SUPPORT Human Clinical

"This subtype was assigned as "USH IV" with a late onset of RP and usually late-onset progressive SNHL without vestibular involvement."

States the progressive, late-onset character of the hearing loss.

🧬

Genetic Associations

1

ARSG (Biallelic ARSG variants cause Usher syndrome type 4. The allelic spectrum spans missense, nonsense and splice variants; every allele subjected to functional testing has shown complete loss of sulfatase activity, and some additionally fail to reach the lysosome. Two founder effects are apparent rather than one: p.D45Y accounts for the Yemenite Jewish families in which the disease was first delineated, and p.(Arg384Trp) recurs among subjects of Portuguese descent. The gene had been known as a lysosomal sulfatase from animal work for years before any human disease was attached to it.)

Gene: ARSG hgnc:24102 relationship_type: CAUSATIVE

Show evidence (3 references)

PMID:29300381 SUPPORT Human Clinical

"Homozygosity for ARSG-p.D45Y in humans leads to protein dysfunction, causing an atypical combination of late-onset Usher syndrome."

Establishes the causal gene-disease relationship.

PMID:39199020 SUPPORT Human Clinical

"Here, we describe nine new subjects and the clinical description of four cases with the USH IV phenotype bearing seven novel and two known pathogenic variants."

Documents the widening allelic spectrum beyond the founder variant.

PMID:39199020 SUPPORT Human Clinical

"novel variant c.1150C>T, p.(Arg384Trp), also present in subjects 4, 5, and 6, all from Portuguese descent"

Documents the second, Portuguese founder allele. No case fraction is curated from this, because the shared-descent grouping is described narratively rather than as a denominator-bearing cohort statistic.

💊

Medical Actions

2

Supportive Sensory Management

Action: Rehabilitation NCIT:C15315

No disease-modifying therapy exists for USH4. Management is sensory support - low-vision rehabilitation, hearing amplification and, where hearing loss is severe, cochlear implantation - together with genetic counselling. No treatment is curated with a target_mechanisms link because nothing available acts on any node of the mechanism above; recording a supportive measure as though it engaged the pathway would misrepresent it.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Autosomal recessive counselling, with the specific wrinkle that late onset means an affected individual has usually completed reproduction before diagnosis, and that ARSG carriers are ascertained through retinal disease rather than through deaf-blindness.

🔬

Diagnosis

4

Molecular Genetic Testing of ARSG

Sequencing of ARSG establishes the diagnosis. Because the retinal phenotype can present as an apparently isolated inherited retinal disease years before hearing loss appears, ARSG belongs on retinal dystrophy gene panels and not only on Usher panels - testing keyed to a deaf-blindness presentation will miss patients during the interval when only the eye is affected.

Genetic Testing NCIT:C15709

Show evidence (1 reference)

PMID:39199020 SUPPORT Human Clinical

"Finally, testing of ARSG should be considered for the genetic work-up of apparent isolated inherited retinal diseases."

The cited authors' own recommendation for how ARSG testing should be deployed.

Vestibular Function Testing

Formal vestibular assessment. Its purpose here is to document an absence: preserved vestibular function is the finding that separates USH4 from USH1, where areflexia is characteristic. The entry asserts that sparing in its phenotype descriptions and differentials, so the test that establishes it belongs in the workup. No NCIT clinical-action term for vestibular function testing could be verified, so the term binding is omitted rather than approximated.

vestibular function testing

Show evidence (1 reference)

PMID:35226187 SUPPORT Human Clinical

"This distinct type of USH is characterized by late-onset RP with predominantly pericentral and macular changes, and late onset SNHL without vestibular dysfunction."

Establishes preserved vestibular function as a defining feature, and therefore as something a workup must positively document.

Arylsulfatase G Enzyme Activity Assay

Functional confirmation that a variant abolishes sulfatase activity. This is the direct readout for the pathophysiology node above, and it is what turned a series of missense variants of uncertain significance into demonstrated nulls across the published cohorts. No suitable NCIT clinical-action term could be verified for a sulfatase activity assay, so the term binding is omitted.

arylsulfatase G enzyme activity assay

Show evidence (1 reference)

PMID:35226187 SUPPORT In Vitro

"Functional experiments indicated a loss of sulfatase activity of the mutant proteins."

Demonstrates the assay's use as functional confirmation of pathogenicity.

Retinal Imaging and Electrophysiology

Optical coherence tomography, fundus autofluorescence and electroretinography characterise the retinal disease. OCT shows loss of the outer retinal layers with relative foveal sparing early on; the ring of atrophy along the arcades is what makes the imaging phenotype suggestive enough to prompt ARSG testing in an apparently isolated retinal dystrophy.

Optical Coherence Tomography NCIT:C20828

Show evidence (1 reference)

PMID:35226187 SUPPORT Human Clinical

"OCT showed complete loss of the outer retinal layers."

Documents optical coherence tomography findings in a molecularly confirmed subject.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Usher Syndrome Type 4:

Usher syndrome types 1, 2 and 3

Overlapping Features The classical Usher types. Distinguished from USH4 by much earlier onset (first or second decade), by the genes involved (stereocilia and connecting-cilium proteins rather than a lysosomal sulfatase), and in type 1 by vestibular areflexia.

Distinguishing Features

USH4 onset is in the fourth decade for both vision and hearing, versus the first or second decade in types 1-3
Vestibular function is preserved in USH4
The retinal atrophy is pericentral and macular rather than mid-peripheral

Show evidence (1 reference)

PMID:35226187 SUPPORT Human Clinical

"This distinct type of USH is characterized by late-onset RP with predominantly pericentral and macular changes, and late onset SNHL without vestibular dysfunction."

States the three features that separate USH4 from the classical types - late onset, pericentral/macular retinal distribution, and preserved vestibular function. The contrasting early-onset and vestibular-areflexia features of types 1-3 appear in this paper's introduction rather than its abstract, so they are stated as curator prose in distinguishing_features and are not attributed to a snippet here.

Mucopolysaccharidosis type IIIE

Overlapping Features Not a mimic but a competing classification of the same molecular defect. Arsg-null mice accumulate heparan sulfate in brain and viscera and are designated MPS IIIE; whether human ARSG deficiency should carry that label instead of, or alongside, USH4 is actively debated. Humans do not show the somatic features of a mucopolysaccharidosis, which is the main argument against.

Distinguishing Features

MPS IIIE has been described only in animal models, never established in humans
Human ARSG patients lack coarse facies, dysostosis multiplex and organomegaly
The human presentation is confined to retina and cochlea

Show evidence (1 reference)

PMID:39202222 SUPPORT Other

"This type of MPS, associated with pathogenic variants in the ARSG gene, has thus far been described only in the context of animal models. However, pathogenic variants in this gene also occur in humans, but are linked to a different disorder, Usher syndrome (USH) type IV, which is sparking..."

States the nosological dispute and that MPS IIIE is so far animal-only.

Isolated inherited retinal disease

Overlapping Features Because hearing loss can follow the retinal disease by a decade or more, USH4 presents for a substantial period as a non-syndromic retinal dystrophy. This is the practical differential most likely to cause a missed diagnosis.

Distinguishing Features

The pericentral ring of atrophy along the arcades is characteristic and should prompt ARSG testing
Hearing loss may not yet have developed at the time of retinal presentation

Show evidence (1 reference)

PMID:39199020 SUPPORT Human Clinical

"These findings highlight that USH IV likely has been underdiagnosed and emphasize the need to test molecularly unresolved subjects with deafblindness syndrome."

The authors' statement that the subtype is under-ascertained.

🐁

Animal Models

2

Arsg knockout mouse

The Arsg-null mouse is both the model on which the MPS IIIE designation rests and the best available model of the retinal disease. Systemically it stores heparan sulfate in central nervous system and viscera. In the retina it loses more than half its photoreceptors by 24 months, with reactive astrogliosis and an outer-retinal microgliosis - and, importantly, without any storage vacuoles. Its retinal arm matches the human disease closely; its systemic storage arm does not match it at all.

Species

Mouse

Genotype

Arsg-null

Publication

PMID:26975023

Pathograph links

Photoreceptor Degeneration recapitulates fidelity: high Progressive, quantified photoreceptor loss with reactive gliosis - the arm of the human disease this model reproduces well, and the reason it is the reference model for USH4 retinal degeneration rather than for the mucopolysaccharidosis it is named after.

Limitations: Onset and tempo are murine, and the mouse shows no storage vacuoles in the retina, so a therapy endpoint defined by clearing retinal storage would have nothing to measure in this model.

Readouts

Photoreceptor cell number

Direction: DECREASED

Interpretation: Quantitative structural correlate of the photoreceptor degeneration node.

Show evidence (1 reference)

PMID:26975023 SUPPORT Model Organism

"Arsg knockout mice showed a progressive degeneration of photoreceptor cells starting between 1 and 6 months of age, resulting in the loss of more than 50% of photoreceptor cells in 24-month-old mice."

Reports the quantified photoreceptor counts grounding this readout.

Show evidence (1 reference)

PMID:26975023 SUPPORT Model Organism

"To our knowledge, this is the first study demonstrating that ARSG deficiency results in progressive photoreceptor degeneration and dysregulation of various lysosomal proteins."

Establishes this model as the primary demonstration that ARSG loss causes photoreceptor degeneration.

Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate partially recapitulates fidelity: moderate Reproduces the enzymatic block and demonstrates that it causes lysosomal heparan sulfate storage - but at a severity and tissue distribution never observed in human ARSG deficiency.

Limitations: Storage is generalised, involving brain, liver and kidney, whereas humans with biallelic ARSG variants show no evidence of generalised lysosomal storage. Using the mouse to predict human systemic disease would therefore overstate the phenotype substantially.

Show evidence (2 references)

PMID:39202222 SUPPORT Model Organism

"The Arsg dysfunction and the deficiency of the corresponding enzyme led to HS accumulation in lysosomes"

Establishes that the mouse model reproduces the lysosomal storage block.

+ 1 more reference

ARSG-mutant American Staffordshire Terrier

A naturally occurring canine ARSG disease carrying p.R99H - the same substitution since found homozygous in a human patient. Dogs develop late-onset progressive ataxia, cerebellar atrophy, Purkinje cell loss and autofluorescent storage, and were proposed as a neuronal ceroid lipofuscinosis. Electroretinography has now shown that they also have rod and cone dysfunction, bringing the retinal arm into line with the human disease while the neurological arm remains unmatched.

Species

Dog

Genotype

ARSG c.296G>A (p.R99H) homozygous

Publication

PMID:41295716

Pathograph links

Photoreceptor Degeneration partially recapitulates fidelity: moderate Affected dogs showing ataxia had attenuated ERG amplitudes indicating rod and cone photoreceptor dysfunction, and autofluorescent inclusions were found in retinal pigment epithelium and ganglion cell layer.

Limitations: Retinal dysfunction in the dog was detected only alongside, and apparently not before, neurological signs, and the storage material is autofluorescent inclusion body rather than the human lesion, for which no retinal histopathology exists.

Readouts

Electroretinogram amplitude

Direction: DECREASED

Interpretation: Functional correlate of rod and cone photoreceptor loss in the canine model.

Show evidence (1 reference)

PMID:41295716 SUPPORT Model Organism

"Three affected dogs that were exhibiting signs of ataxia had attenuated electroretinogram (ERG) amplitudes indicative of rod and cone photoreceptor dysfunction"

Reports the ERG measurement grounding this readout.

Show evidence (1 reference)

PMID:41295716 SUPPORT Model Organism

"Autofluorescent inclusions were observed in the retinal pigment epithelium and retinal ganglion cell layer of two affected dogs that were euthanized due to neurological disease progression."

Establishes retinal involvement in the canine model at the tissue level.

Late-Onset Deaf-Blindness fails to recapitulate fidelity: low The canine disease is dominated by progressive ataxia and cerebellar degeneration. The human disease has essentially no neurological component, and the defining human endpoint - combined late-onset visual and auditory loss - is not what the dogs present with.

Limitations: This is the sharpest available statement of the species divergence, because it is variant-matched: a human homozygous for the very same p.R99H allele that makes these dogs ataxic had no neurological signs at age 74. The dog therefore cannot be used to model the human clinical course, and a therapeutic endpoint validated in dogs (ataxia) has no human counterpart.

Show evidence (2 references)

PMID:41295716 SUPPORT Human Clinical

"In contrast to ASTs and mice with ARSG mutations, human patients generally do not exhibit neurological involvement, with the exception of two patients reported to have mild cerebellar atrophy without ataxia"

States directly that the neurological phenotype of the canine and murine models is not reproduced in human patients.

+ 1 more reference

{ }

Source YAML

click to show

name: Usher Syndrome Type 4
creation_date: "2026-08-21T00:00:00Z"
category: Mendelian
description: >-
  Usher syndrome type 4 (USH4, OMIM 618144) is an ultra-rare autosomal recessive
  deaf-blindness syndrome caused by biallelic loss-of-function variants in ARSG,
  which encodes the lysosomal sulfatase arylsulfatase G. ARSG removes 3-O-sulfate
  from glucosamine residues during the nine-enzyme lysosomal degradation of
  heparan sulfate, so USH4 is mechanistically a defect of glycosaminoglycan
  catabolism rather than of the stereocilia/photoreceptor-connecting-cilium
  machinery that underlies Usher types 1-3.

  Three features separate it clinically from the classical types: onset is
  strikingly late, typically in the fourth decade rather than in childhood; the
  retinal disease is pericentral and macular, with ring-shaped atrophy along the
  vascular arcades encircling the fovea; and vestibular function is spared. It
  was recognised only in 2018 and remains under-ascertained - a 2024 series that
  added nine subjects expanded the known case count by more than 30%.

  The gene's cross-species behaviour is the entry's central puzzle. Arsg-null
  mice accumulate heparan sulfate in brain, liver and kidney and are classified
  as mucopolysaccharidosis IIIE; ARSG-mutant dogs develop ataxia, cerebellar
  atrophy and autofluorescent storage and were proposed as a neuronal ceroid
  lipofuscinosis. Humans carrying the same lesions get neither. That divergence
  is curated here as a HUMAN_MODEL_MISMATCH and as an open nosological
  CONTROVERSY, not resolved in favour of either reading.
disease_term:
  preferred_term: Usher syndrome, type 4
  term:
    id: MONDO:0029141
    label: Usher syndrome, type 4
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    USH4 segregates as an autosomal recessive trait. Affected individuals are
    homozygous or compound heterozygous for ARSG variants; the first-described
    families carried a homozygous founder allele and were consanguineous or from
    a genetically isolated population.
  evidence:
  - reference: PMID:33300174
    reference_title: "New clinical and molecular evidence linking mutations in ARSG to Usher syndrome type IV."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified three novel pathogenic variants in ARSG, which segregated
      recessively with the disease in two families from Portugal"
    explanation: States recessive segregation of ARSG variants in two independent families.

pathophysiology:
- name: Biallelic ARSG Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Homozygous or compound heterozygous variants in ARSG (hgnc:24102) are the
    initiating lesion. Reported alleles include missense changes affecting the
    catalytic site, nonsense and splice alleles. The founder allele in the first
    families, c.133G>T (p.D45Y), alters a fully conserved residue of the enzyme's
    catalytic site.
  downstream:
  - target: Abolished Arylsulfatase G Sulfatase Activity
    causal_link_type: DIRECT
  - target: Failed Lysosomal Targeting with ER Retention
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a homozygous founder missense variant, c.133G>T (p.D45Y)
      in arylsulfatase G (ARSG)"
    explanation: Identifies the founding biallelic ARSG lesion.
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The identified variant affected a fully conserved amino acid that is
      part of the catalytic site of the enzyme."
    explanation: Locates the founder variant in the catalytic site, explaining loss of activity.

- name: Abolished Arylsulfatase G Sulfatase Activity
  biological_scale: MOLECULAR
  description: >-
    USH4 alleles tested functionally show complete loss of sulfatase activity, not
    a graded reduction. This has held across independently ascertained cohorts and
    across missense, nonsense and splice alleles, which is why the disease behaves
    as a clean enzyme-null state.
  molecular_functions:
  - preferred_term: arylsulfatase G sulfatase activity
    term:
      id: GO:0008484
      label: sulfuric ester hydrolase activity
    modifier: LOSS_OF_FUNCTION
  downstream:
  - target: Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional analysis of the wild-type and mutant proteins showed no basal
      activity of p.D45Y."
    explanation: Direct demonstration that the founder allele abolishes enzyme activity.
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional experiments indicated the complete loss of sulfatase enzymatic
      activity upon ectopic expression of mutated ARSG cDNA."
    explanation: Confirms complete loss of activity across a further set of nine subjects' alleles.
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional experiments indicated a loss of sulfatase activity of the mutant
      proteins."
    explanation: Independent replication of the enzyme-null result in three unrelated subjects.

- name: Failed Lysosomal Targeting with ER Retention
  biological_scale: CELLULAR
  description: >-
    A second, parallel route to the same end point. Some pathogenic ARSG variants
    do not merely inactivate the enzyme in place - they prevent it reaching the
    lysosome at all, leaving the protein retained in the endoplasmic reticulum.
    Curated as its own node rather than folded into catalytic loss because it is a
    distinct molecular failure that would not be corrected by a strategy aimed
    only at restoring catalysis.
  cellular_components:
  - preferred_term: endoplasmic reticulum
    term:
      id: GO:0005783
      label: endoplasmic reticulum
  biological_processes:
  - preferred_term: protein localization to lysosome
    term:
      id: GO:0061462
      label: protein localization to lysosome
    modifier: DECREASED
  downstream:
  - target: Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:33300174
    reference_title: "New clinical and molecular evidence linking mutations in ARSG to Usher syndrome type IV."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "these pathogenic variants abolish the sulfatase activity of the Arylsulfatase
      G enzyme and impede the appropriate lysosomal localization of the protein product,
      which appears to be retained in the endoplasmic reticulum"
    explanation: >-
      Establishes mislocalization with ER retention as a mechanism accompanying
      catalytic loss for these alleles.

- name: Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate
  biological_scale: CELLULAR
  description: >-
    ARSG catalyses one obligate step in the nine-enzyme lysosomal heparan sulfate
    degradation pathway: removal of 3-O-sulfate from glucosamine. Losing it stalls
    the sequential catabolic chain at that residue. In mouse and dog this produces
    frank, generalised storage; in humans no generalised storage phenotype has been
    demonstrated, which is why the downstream node here is confined to the retina
    and cochlea.
  biological_processes:
  - preferred_term: heparan sulfate proteoglycan catabolic process
    term:
      id: GO:0030200
      label: heparan sulfate proteoglycan catabolic process
    modifier: DECREASED
  downstream:
  - target: RPE-Restricted ARSG Loss
    causal_link_type: DIRECT
  - target: Cochlear Sensory Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:34405855
    reference_title: "Decoding the consecutive lysosomal degradation of 3-O-sulfate containing heparan sulfate by Arylsulfatase G (ARSG)."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Within this degradation pathway, Arylsulfatase G (ARSG) is critical for
      removing 3-O-sulfate from glucosamine, and mutations in ARSG are causative for
      Usher syndrome type IV."
    explanation: Defines the precise enzymatic step ARSG performs and links its loss to USH4.
  - reference: PMID:34405855
    reference_title: "Decoding the consecutive lysosomal degradation of 3-O-sulfate containing heparan sulfate by Arylsulfatase G (ARSG)."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The lysosomal degradation of heparan sulfate is mediated by the concerted
      action of nine different enzymes."
    explanation: Establishes that ARSG acts within an obligate multi-enzyme sequential pathway.

- name: RPE-Restricted ARSG Loss
  biological_scale: CELLULAR
  description: >-
    In the retina, ARSG is not expressed where the disease is seen. In wild-type mouse
    retina the protein is detectable only in the retinal pigment epithelium, yet it is the
    photoreceptors that degenerate - so the photoreceptor loss is cell-non-autonomous,
    driven from the RPE.

    What the RPE does next is genuinely unresolved, and the two available species disagree.
    In Arsg-null mice the RPE is morphologically normal on electron microscopy and no
    storage vacuoles are found anywhere in the retina, which argues against a simple
    storage-crushes-the-RPE account. In ARSG-mutant dogs the RPE does accumulate
    autofluorescent storage bodies. The proposal that this perturbs the RPE-photoreceptor
    interactions required for photoreceptor maintenance is exactly that - the canine study
    states that the mechanism "remains to be elucidated". The node is therefore curated for
    what is established, the RPE-restricted site of action, with the downstream edge left
    as having unknown intermediates.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  downstream:
  - target: Photoreceptor Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:26975023
    reference_title: "Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Of note, expression of ARSG protein in wild-type mice was detectable only in
      the RPE which, however, appeared morphologically unaffected in knockout mice at the
      electron microscopic level."
    explanation: >-
      Establishes both halves of this node: ARSG acts in the RPE rather than in
      photoreceptors, and the RPE nonetheless looks normal, so the mechanism is not simple
      RPE storage pathology.
  - reference: PMID:26975023
    reference_title: "Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Electron microscopic analyses of retinas revealed no evidence for the presence
      of storage vacuoles."
    explanation: >-
      Curated as PARTIAL because it is a negative finding that constrains the mechanism
      rather than supporting a positive one - it argues against storage-driven retinal
      degeneration in the mouse.
  - reference: PMID:41295716
    reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the finding that the RPE of affected dogs accumulated autofluorescent storage
      bodies suggests that disease-related RPE pathology may alter the RPE–photoreceptor
      cell interactions that are necessary for maintaining normal photoreceptor cell
      functions"
    explanation: >-
      The canine counterpart, curated as PARTIAL because the same paragraph states the
      mechanism remains to be elucidated and because canine RPE storage is not seen in the
      mouse.

- name: Photoreceptor Degeneration
  biological_scale: CELLULAR
  description: >-
    Rod and cone photoreceptors degenerate, producing a rod-cone dystrophy. The
    intermediate steps between stalled heparan sulfate catabolism and photoreceptor
    death are not established in human tissue, so the incoming edge is curated as
    having unknown intermediates.
  cell_types:
  - preferred_term: retinal rod cell
    term:
      id: CL:0000604
      label: retinal rod cell
  - preferred_term: retinal cone cell
    term:
      id: CL:0000573
      label: retinal cone cell
  downstream:
  - target: Pericentral and Macular Retinal Atrophy
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This subtype was assigned as \"USH IV\" with a late onset of RP and usually
      late-onset progressive SNHL without vestibular involvement."
    explanation: Establishes retinitis pigmentosa (rod-cone dystrophy) as the retinal phenotype of USH4.

- name: Pericentral and Macular Retinal Atrophy
  biological_scale: TISSUE
  description: >-
    The distinctive structural lesion of USH4: ring-shaped atrophy running along the
    vascular arcades and encircling the fovea, giving a ring scotoma. The pattern is
    pericentral and macular rather than the mid-peripheral bone-spicule pattern of
    typical retinitis pigmentosa, and it is specific enough that it can suggest ARSG
    testing in an apparently isolated retinal dystrophy.
  downstream:
  - target: Late-Onset Deaf-Blindness
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients shared a distinctive retinal phenotype with ring-shaped atrophy
      along the arcades engirdling the fovea, resulting in ring scotoma."
    explanation: Describes the characteristic retinal lesion in all five founding patients.
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This distinct type of USH is characterized by late-onset RP with predominantly
      pericentral and macular changes, and late onset SNHL without vestibular dysfunction."
    explanation: Independent confirmation of the pericentral/macular distribution.

- name: Cochlear Sensory Dysfunction
  biological_scale: TISSUE
  description: >-
    Progressive sensorineural hearing loss develops, typically after the retinal
    disease and usually in the fifth decade or later. Vestibular function is
    preserved - the labyrinth is spared even though the cochlea is not. No human
    cochlear histopathology is available for USH4, so the cell-type annotation
    below is the expected sensory target rather than a demonstrated site of injury.
  cell_types:
  - preferred_term: cochlear inner hair cell
    term:
      id: CL:0000589
      label: cochlear inner hair cell
  downstream:
  - target: Late-Onset Deaf-Blindness
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In addition, patients developed moderate to severe sensorineural hearing loss."
    explanation: Establishes sensorineural hearing loss in the founding cohort.

- name: Late-Onset Deaf-Blindness
  biological_scale: ORGANISM
  description: >-
    The combined sensory endpoint. What distinguishes USH4 from every other Usher
    type is when it arrives: both the visual and the auditory loss begin around the
    fourth decade, rather than in the first or second as in types 1-3. A patient can
    therefore complete education and working life before either deficit declares
    itself.
  evidence:
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both vision and hearing loss appeared around the age of 40 years."
    explanation: Establishes the late, near-simultaneous onset that defines the subtype.
  - reference: PMID:33300174
    reference_title: "New clinical and molecular evidence linking mutations in ARSG to Usher syndrome type IV."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The probands were affected with retinitis pigmentosa and sensorineural hearing
      loss, generally with an onset of symptoms in their fourth decade of life."
    explanation: Independent replication of fourth-decade onset in Portuguese families.

phenotypes:
- category: Ophthalmological
  name: Rod-Cone Dystrophy
  description: >-
    Progressive rod-cone dystrophy (retinitis pigmentosa) with late onset. Present in
    essentially all reported subjects and usually the presenting problem.
  phenotype_term:
    preferred_term: Rod-cone dystrophy
    term:
      id: HP:0000510
      label: Rod-cone dystrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:41295716
    reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most of these patients display hearing loss and rod-cone dystrophy."
    explanation: States rod-cone dystrophy as the dominant retinal phenotype across reported ARSG cases.

- category: Ophthalmological
  name: Pericentral Retinitis Pigmentosa
  description: >-
    The retinal degeneration is distributed pericentrally and at the macula, producing
    ring-shaped atrophy along the arcades rather than the mid-peripheral pattern of
    typical RP.
  phenotype_term:
    preferred_term: Pericentral retinitis pigmentosa
    term:
      id: HP:0007947
      label: Pericentral retinitis pigmentosa
  evidence:
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This distinct type of USH is characterized by late-onset RP with predominantly
      pericentral and macular changes, and late onset SNHL without vestibular dysfunction."
    explanation: Directly states the pericentral and macular distribution of the retinopathy.

- category: Ophthalmological
  name: Bone Spicule Pigmentation
  description: >-
    Intraretinal bone spicule pigmentation, distributed peripherally around the ring of
    atrophy and best seen nasally and superior to the optic disc - a different distribution
    from the mid-peripheral pattern of typical retinitis pigmentosa.
  phenotype_term:
    preferred_term: Intraretinal bone spicule pigmentation
    term:
      id: HP:0007737
      label: Spicular pigmentation of the retina
  evidence:
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The retinal phenotype is characterized by a specific distribution of atrophy
      around the arcades, peripherally surrounded by intraretinal bone spicules best
      appreciated nasally and superior to the disc."
    explanation: Describes the bone spicule pigmentation and its characteristic distribution.

- category: Audiological
  name: Progressive Sensorineural Hearing Impairment
  description: >-
    Progressive sensorineural hearing loss, generally later in onset than the retinal
    disease and without vestibular involvement.
  phenotype_term:
    preferred_term: Progressive sensorineural hearing impairment
    term:
      id: HP:0000408
      label: Progressive sensorineural hearing impairment
  evidence:
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This subtype was assigned as \"USH IV\" with a late onset of RP and usually
      late-onset progressive SNHL without vestibular involvement."
    explanation: States the progressive, late-onset character of the hearing loss.

- category: Ophthalmological
  name: Nyctalopia
  description: >-
    Night blindness, the usual first symptom of the rod-predominant phase, reported
    from the early forties in a molecularly confirmed homozygote.
  phenotype_term:
    preferred_term: Nyctalopia
    term:
      id: HP:0000662
      label: Nyctalopia
  evidence:
  - reference: PMID:41295716
    reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The homozygous p.R99H patient reported night blindness and photophobia
      starting in his early 40s and progressive hearing loss starting in his 50s."
    explanation: Documents night blindness with age of onset in a confirmed ARSG homozygote.

- category: Ophthalmological
  name: Photophobia
  description: Photophobia reported alongside night blindness in the fourth decade.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:41295716
    reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The homozygous p.R99H patient reported night blindness and photophobia
      starting in his early 40s and progressive hearing loss starting in his 50s."
    explanation: Documents photophobia in a confirmed ARSG homozygote.

genetic:
- name: ARSG
  gene_term:
    preferred_term: ARSG
    term:
      id: hgnc:24102
      label: ARSG
  relationship_type: CAUSATIVE
  association: >-
    Biallelic ARSG variants cause Usher syndrome type 4. The allelic spectrum spans
    missense, nonsense and splice variants; every allele subjected to functional
    testing has shown complete loss of sulfatase activity, and some additionally fail
    to reach the lysosome. Two founder effects are apparent rather than one: p.D45Y
    accounts for the Yemenite Jewish families in which the disease was first delineated,
    and p.(Arg384Trp) recurs among subjects of Portuguese descent. The gene had been known
    as a lysosomal sulfatase from animal work for years before any human disease was
    attached to it.
  evidence:
  - reference: PMID:29300381
    reference_title: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Homozygosity for ARSG-p.D45Y in humans leads to protein dysfunction, causing
      an atypical combination of late-onset Usher syndrome."
    explanation: Establishes the causal gene-disease relationship.
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we describe nine new subjects and the clinical description of four cases
      with the USH IV phenotype bearing seven novel and two known pathogenic variants."
    explanation: Documents the widening allelic spectrum beyond the founder variant.
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "novel variant c.1150C>T, p.(Arg384Trp), also present in subjects 4, 5, and 6,
      all from Portuguese descent"
    explanation: >-
      Documents the second, Portuguese founder allele. No case fraction is curated from this,
      because the shared-descent grouping is described narratively rather than as a
      denominator-bearing cohort statistic.

diagnosis:
- name: Molecular Genetic Testing of ARSG
  description: >-
    Sequencing of ARSG establishes the diagnosis. Because the retinal phenotype can
    present as an apparently isolated inherited retinal disease years before hearing
    loss appears, ARSG belongs on retinal dystrophy gene panels and not only on Usher
    panels - testing keyed to a deaf-blindness presentation will miss patients during
    the interval when only the eye is affected.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, testing of ARSG should be considered for the genetic work-up of
      apparent isolated inherited retinal diseases."
    explanation: The cited authors' own recommendation for how ARSG testing should be deployed.

- name: Vestibular Function Testing
  description: >-
    Formal vestibular assessment. Its purpose here is to document an absence: preserved
    vestibular function is the finding that separates USH4 from USH1, where areflexia is
    characteristic. The entry asserts that sparing in its phenotype descriptions and
    differentials, so the test that establishes it belongs in the workup. No NCIT
    clinical-action term for vestibular function testing could be verified, so the term
    binding is omitted rather than approximated.
  diagnosis_term:
    preferred_term: vestibular function testing
  evidence:
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This distinct type of USH is characterized by late-onset RP with predominantly
      pericentral and macular changes, and late onset SNHL without vestibular dysfunction."
    explanation: >-
      Establishes preserved vestibular function as a defining feature, and therefore as
      something a workup must positively document.

- name: Arylsulfatase G Enzyme Activity Assay
  description: >-
    Functional confirmation that a variant abolishes sulfatase activity. This is the direct
    readout for the pathophysiology node above, and it is what turned a series of missense
    variants of uncertain significance into demonstrated nulls across the published
    cohorts. No suitable NCIT clinical-action term could be verified for a sulfatase
    activity assay, so the term binding is omitted.
  diagnosis_term:
    preferred_term: arylsulfatase G enzyme activity assay
  evidence:
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional experiments indicated a loss of sulfatase activity of the mutant
      proteins."
    explanation: Demonstrates the assay's use as functional confirmation of pathogenicity.

- name: Retinal Imaging and Electrophysiology
  description: >-
    Optical coherence tomography, fundus autofluorescence and electroretinography
    characterise the retinal disease. OCT shows loss of the outer retinal layers with
    relative foveal sparing early on; the ring of atrophy along the arcades is what makes
    the imaging phenotype suggestive enough to prompt ARSG testing in an apparently
    isolated retinal dystrophy.
  diagnosis_term:
    preferred_term: Optical Coherence Tomography
    term:
      id: NCIT:C20828
      label: Optical Coherence Tomography
  evidence:
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "OCT showed complete loss of the outer retinal layers."
    explanation: Documents optical coherence tomography findings in a molecularly confirmed subject.

treatments:
- name: Supportive Sensory Management
  description: >-
    No disease-modifying therapy exists for USH4. Management is sensory support -
    low-vision rehabilitation, hearing amplification and, where hearing loss is
    severe, cochlear implantation - together with genetic counselling. No treatment
    is curated with a target_mechanisms link because nothing available acts on any
    node of the mechanism above; recording a supportive measure as though it engaged
    the pathway would misrepresent it.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation

- name: Genetic Counseling
  description: >-
    Autosomal recessive counselling, with the specific wrinkle that late onset means
    an affected individual has usually completed reproduction before diagnosis, and
    that ARSG carriers are ascertained through retinal disease rather than through
    deaf-blindness.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling

differential_diagnoses:
- name: Usher syndrome types 1, 2 and 3
  description: >-
    The classical Usher types. Distinguished from USH4 by much earlier onset (first
    or second decade), by the genes involved (stereocilia and connecting-cilium
    proteins rather than a lysosomal sulfatase), and in type 1 by vestibular areflexia.
  distinguishing_features:
  - USH4 onset is in the fourth decade for both vision and hearing, versus the first or second decade in types 1-3
  - Vestibular function is preserved in USH4
  - The retinal atrophy is pericentral and macular rather than mid-peripheral
  evidence:
  - reference: PMID:35226187
    reference_title: "Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This distinct type of USH is characterized by late-onset RP with predominantly
      pericentral and macular changes, and late onset SNHL without vestibular dysfunction."
    explanation: >-
      States the three features that separate USH4 from the classical types - late onset,
      pericentral/macular retinal distribution, and preserved vestibular function. The
      contrasting early-onset and vestibular-areflexia features of types 1-3 appear in this
      paper's introduction rather than its abstract, so they are stated as curator prose in
      distinguishing_features and are not attributed to a snippet here.

- name: Mucopolysaccharidosis type IIIE
  description: >-
    Not a mimic but a competing classification of the same molecular defect. Arsg-null
    mice accumulate heparan sulfate in brain and viscera and are designated MPS IIIE;
    whether human ARSG deficiency should carry that label instead of, or alongside,
    USH4 is actively debated. Humans do not show the somatic features of a
    mucopolysaccharidosis, which is the main argument against.
  distinguishing_features:
  - MPS IIIE has been described only in animal models, never established in humans
  - Human ARSG patients lack coarse facies, dysostosis multiplex and organomegaly
  - The human presentation is confined to retina and cochlea
  evidence:
  - reference: PMID:39202222
    reference_title: "Mucopolysaccharidosis Type IIIE: A Real Human Disease or a Diagnostic Pitfall?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This type of MPS, associated with pathogenic variants in the ARSG gene, has
      thus far been described only in the context of animal models. However, pathogenic
      variants in this gene also occur in humans, but are linked to a different disorder,
      Usher syndrome (USH) type IV, which is sparking increasing debate."
    explanation: States the nosological dispute and that MPS IIIE is so far animal-only.

- name: Isolated inherited retinal disease
  description: >-
    Because hearing loss can follow the retinal disease by a decade or more, USH4
    presents for a substantial period as a non-syndromic retinal dystrophy. This is
    the practical differential most likely to cause a missed diagnosis.
  distinguishing_features:
  - The pericentral ring of atrophy along the arcades is characteristic and should prompt ARSG testing
  - Hearing loss may not yet have developed at the time of retinal presentation
  evidence:
  - reference: PMID:39199020
    reference_title: "Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings highlight that USH IV likely has been underdiagnosed and
      emphasize the need to test molecularly unresolved subjects with deafblindness syndrome."
    explanation: The authors' statement that the subtype is under-ascertained.

animal_models:
- name: Arsg knockout mouse
  species: Mouse
  genotype: Arsg-null
  publication: PMID:26975023
  description: >-
    The Arsg-null mouse is both the model on which the MPS IIIE designation rests and the
    best available model of the retinal disease. Systemically it stores heparan sulfate in
    central nervous system and viscera. In the retina it loses more than half its
    photoreceptors by 24 months, with reactive astrogliosis and an outer-retinal
    microgliosis - and, importantly, without any storage vacuoles. Its retinal arm matches
    the human disease closely; its systemic storage arm does not match it at all.
  modeled_mechanisms:
  - target: Photoreceptor Degeneration
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      Progressive, quantified photoreceptor loss with reactive gliosis - the arm of the
      human disease this model reproduces well, and the reason it is the reference model
      for USH4 retinal degeneration rather than for the mucopolysaccharidosis it is named
      after.
    limitations: >-
      Onset and tempo are murine, and the mouse shows no storage vacuoles in the retina,
      so a therapy endpoint defined by clearing retinal storage would have nothing to
      measure in this model.
    readouts:
    - name: Photoreceptor cell number
      target: Photoreceptor Degeneration
      direction: DECREASED
      interpretation: Quantitative structural correlate of the photoreceptor degeneration node.
      evidence:
      - reference: PMID:26975023
        reference_title: "Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Arsg knockout mice showed a progressive degeneration of photoreceptor cells
          starting between 1 and 6 months of age, resulting in the loss of more than 50% of
          photoreceptor cells in 24-month-old mice."
        explanation: Reports the quantified photoreceptor counts grounding this readout.
    evidence:
    - reference: PMID:26975023
      reference_title: "Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "To our knowledge, this is the first study demonstrating that ARSG deficiency
        results in progressive photoreceptor degeneration and dysregulation of various
        lysosomal proteins."
      explanation: >-
        Establishes this model as the primary demonstration that ARSG loss causes
        photoreceptor degeneration.
  - target: Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the enzymatic block and demonstrates that it causes lysosomal heparan
      sulfate storage - but at a severity and tissue distribution never observed in
      human ARSG deficiency.
    limitations: >-
      Storage is generalised, involving brain, liver and kidney, whereas humans with
      biallelic ARSG variants show no evidence of generalised lysosomal storage. Using
      the mouse to predict human systemic disease would therefore overstate the
      phenotype substantially.
    evidence:
    - reference: PMID:39202222
      reference_title: "Mucopolysaccharidosis Type IIIE: A Real Human Disease or a Diagnostic Pitfall?"
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "The Arsg dysfunction and the deficiency of the corresponding enzyme led to
        HS accumulation in lysosomes"
      explanation: Establishes that the mouse model reproduces the lysosomal storage block.
    - reference: PMID:39202222
      reference_title: "Mucopolysaccharidosis Type IIIE: A Real Human Disease or a Diagnostic Pitfall?"
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "HS storage was evident in both CNS and somatic organs, like the liver and kidney"
      explanation: >-
        Documents the generalised distribution of storage in the mouse, which is the
        respect in which it diverges from the human disease.

- name: ARSG-mutant American Staffordshire Terrier
  species: Dog
  genotype: ARSG c.296G>A (p.R99H) homozygous
  publication: PMID:41295716
  description: >-
    A naturally occurring canine ARSG disease carrying p.R99H - the same substitution
    since found homozygous in a human patient. Dogs develop late-onset progressive
    ataxia, cerebellar atrophy, Purkinje cell loss and autofluorescent storage, and
    were proposed as a neuronal ceroid lipofuscinosis. Electroretinography has now
    shown that they also have rod and cone dysfunction, bringing the retinal arm into
    line with the human disease while the neurological arm remains unmatched.
  modeled_mechanisms:
  - target: Photoreceptor Degeneration
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Affected dogs showing ataxia had attenuated ERG amplitudes indicating rod and cone
      photoreceptor dysfunction, and autofluorescent inclusions were found in retinal
      pigment epithelium and ganglion cell layer.
    limitations: >-
      Retinal dysfunction in the dog was detected only alongside, and apparently not
      before, neurological signs, and the storage material is autofluorescent inclusion
      body rather than the human lesion, for which no retinal histopathology exists.
    readouts:
    - name: Electroretinogram amplitude
      target: Photoreceptor Degeneration
      direction: DECREASED
      interpretation: Functional correlate of rod and cone photoreceptor loss in the canine model.
      evidence:
      - reference: PMID:41295716
        reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Three affected dogs that were exhibiting signs of ataxia had attenuated
          electroretinogram (ERG) amplitudes indicative of rod and cone photoreceptor dysfunction"
        explanation: Reports the ERG measurement grounding this readout.
    evidence:
    - reference: PMID:41295716
      reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Autofluorescent inclusions were observed in the retinal pigment epithelium and
        retinal ganglion cell layer of two affected dogs that were euthanized due to
        neurological disease progression."
      explanation: Establishes retinal involvement in the canine model at the tissue level.
  - target: Late-Onset Deaf-Blindness
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      The canine disease is dominated by progressive ataxia and cerebellar degeneration.
      The human disease has essentially no neurological component, and the defining human
      endpoint - combined late-onset visual and auditory loss - is not what the dogs
      present with.
    limitations: >-
      This is the sharpest available statement of the species divergence, because it is
      variant-matched: a human homozygous for the very same p.R99H allele that makes these
      dogs ataxic had no neurological signs at age 74. The dog therefore cannot be used
      to model the human clinical course, and a therapeutic endpoint validated in dogs
      (ataxia) has no human counterpart.
    evidence:
    - reference: PMID:41295716
      reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In contrast to ASTs and mice with ARSG mutations, human patients generally do
        not exhibit neurological involvement, with the exception of two patients reported to
        have mild cerebellar atrophy without ataxia"
      explanation: >-
        States directly that the neurological phenotype of the canine and murine models is
        not reproduced in human patients.
    - reference: PMID:41295716
      reference_title: "Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Neither patient exhibited any neurologic signs as of age 74 (homozygous
        patient) and age 55 (heterozygous patient)."
      explanation: >-
        The variant-matched human observation: a p.R99H homozygote, same allele as the
        affected dogs, was neurologically normal at 74.

discussions:
- discussion_id: mismatch_arsg_species_divergence
  kind: HUMAN_MODEL_MISMATCH
  attaches_to:
  - pathophysiology#Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate
  prompt: >-
    Why does the same enzymatic block produce generalised lysosomal storage with
    neurodegeneration in mouse and dog, but disease confined to retina and cochlea in
    humans - even for carriers of the identical p.R99H allele?
  rationale: >-
    This is not the usual model-fidelity caveat, where a model shows a milder or partial
    version of the human disease. Here the models show a substantially different and in
    some respects more severe disease, and the discrepancy is anchored at the level of a
    single shared variant. A human homozygous for p.R99H was neurologically intact at 74
    while dogs homozygous for the same substitution lose the ability to stand. Any
    explanation has to account for that: candidate reasons include species differences
    in heparan sulfate 3-O-sulfation load, redundancy from another sulfatase in humans,
    lifespan and cell-turnover differences, or simply that the human neurological
    phenotype is subclinical - the two reported patients with mild cerebellar atrophy
    but no ataxia are the only hint of the latter. Which is true determines whether human
    USH4 should be watched for late neurological decline, and whether the mouse and dog
    can serve as preclinical models for a therapy aimed at the human disease.
  proposed_experiments:
  - experiment_id: exp_arsg_neuroimaging_cohort
    name: Systematic neurological and cerebellar imaging of an ARSG cohort
    description: >-
      Prospectively image the cerebellum and perform standardised neurological
      examination across the reported ARSG cohort, stratified by age and genotype. Two
      patients with mild cerebellar atrophy without ataxia have been noted incidentally;
      only systematic assessment can establish whether subclinical cerebellar involvement
      is the rule and simply never reaches the threshold that ataxia in dogs does.
  - experiment_id: exp_arsg_substrate_load_comparison
    name: Cross-species quantification of 3-O-sulfated heparan sulfate substrate load
    description: >-
      Measure 3-O-sulfated heparan sulfate content and the activity of the other eight
      enzymes of the pathway in matched human, canine and murine tissues. If human
      neural tissue simply presents less of the ARSG-dependent substrate, or has greater
      redundancy at that step, the species divergence would be explained without invoking
      a difference in the enzyme itself.

- discussion_id: controversy_mps_iiie_versus_usher_iv
  kind: CONTROVERSY
  attaches_to:
  - pathophysiology#Impaired Lysosomal Degradation of 3-O-Sulfated Heparan Sulfate
  prompt: >-
    Should human ARSG deficiency be classified as Usher syndrome type 4, as a thirteenth
    mucopolysaccharidosis (MPS IIIE), or as both?
  rationale: >-
    ARSG is unambiguously a lysosomal sulfatase acting in heparan sulfate degradation,
    which is the definitional criterion for a mucopolysaccharidosis, and the animal models
    store glycosaminoglycan exactly as an MPS should. Against that, the human phenotype
    has none of the somatic hallmarks of an MPS - no coarse facies, no dysostosis
    multiplex, no organomegaly - and human GAG accumulation has not been demonstrated. The
    disease was therefore named for what it looks like clinically rather than for the
    pathway it disrupts. This entry curates it as USH4, following MONDO and OMIM, while
    recording that the classification is contested rather than settled; the practical
    stake is whether these patients should be enrolled in MPS natural-history studies and
    offered MPS-directed therapies.
  proposed_experiments:
  - experiment_id: exp_human_gag_storage_assessment
    name: Direct assessment of glycosaminoglycan storage in ARSG-deficient humans
    description: >-
      Measure urinary and tissue glycosaminoglycans, and specifically 3-O-sulfated
      heparan sulfate species, in molecularly confirmed ARSG patients against matched
      controls. The MPS IIIE argument currently rests on the animal models plus the
      enzyme's known function; a direct negative result in humans would largely settle it,
      and a positive one would reopen the therapeutic question.

notes: >-
  Epidemiology. USH4 is ultra-rare and under-ascertained: roughly 31 cases had been
  reported by 2025, and the largest single addition - nine subjects in 2024 - increased
  the known total by more than 30%, which indicates how incomplete ascertainment remains.
  No population prevalence estimate exists for the subtype itself, so none is curated;
  the available figures are for Usher syndrome as a whole.

  No GeneReviews chapter exists for USH4 or ARSG. This was checked directly rather than
  assumed: a PubMed search for ARSG in GeneReviews returns nothing, and the two Usher
  GeneReviews chapters that do exist (PMID:20301442 and PMID:20301515) cover types I and
  II and contain no mention of ARSG, USH4 or type IV. The mandatory GeneReviews baseline
  therefore does not apply here, and neither chapter is cited, since quoting a type I or
  type II chapter in support of a type 4 claim would be evidence from the wrong disease.

  No frequency bands are assigned to any phenotype in this entry. With roughly 31 reported
  cases and no systematic cohort denominator, a band would imply a precision the literature
  does not have.

  The absence of vestibular dysfunction is diagnostically important and is stated in the
  descriptions and differentials, but is deliberately not curated as a phenotype: it is a
  negative finding, and the schema's phenotype list is for features that are present.

references:
- reference: PMID:26975023
  title: Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice.
- reference: PMID:29300381
  title: A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic
    activity causing atypical Usher syndrome in humans.
- reference: PMID:39199020
  title: Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic
    ARSG variants.
- reference: PMID:41295716
  title: Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset
    Neurodegenerative Disease Associated with an ARSG Variant.

📚

References & Deep Research

References

4

PMID:26975023

Degeneration of Photoreceptor Cells in Arylsulfatase G-Deficient Mice.

No top-level findings curated for this source.

PMID:29300381

A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans.

No top-level findings curated for this source.

PMID:39199020

Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants.

No top-level findings curated for this source.

PMID:41295716

Retinal Function Deficits in American Staffordshire Terriers with a Late-Onset Neurodegenerative Disease Associated with an ARSG Variant.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Usher Syndrome Type 4 (USH4): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 12 citations 2026-08-21T12:48:48.206173

Usher Syndrome Type 4 (USH4): Comprehensive Research Report

1. Disease Information

Overview

Usher syndrome type IV (USH4) is a rare, autosomal recessive, atypical form of Usher syndrome characterized by late-onset retinitis pigmentosa (RP) with a distinctive pericentral/macular pattern and late-onset, progressive sensorineural hearing loss (SNHL) occurring without vestibular dysfunction. It is caused by biallelic pathogenic variants in ARSG (arylsulfatase G), a lysosomal sulfatase gene, and was only formally delineated as a distinct Usher subtype in 2018 — decades after Usher types I–III were characterized (Khateb et al. 2018, PMID:29300381; OMIM #618144).

USH4 is clinically distinguished from USH1–3 chiefly by the markedly later onset of both sensory deficits (visual symptoms typically in the 3rd–6th decade rather than childhood) and by the complete absence of vestibular involvement, which sets it apart even from USH2 and USH3 in most reported cases (Peter et al. 2022, PMID:35226187).

Key Identifiers

Resource	Identifier
OMIM (phenotype)	#618144 — Usher Syndrome, Type IV; USH4
OMIM (gene)	*610008 — Arylsulfatase G; ARSG
Gene locus	Chromosome 17q24.2
MONDO	Usher syndrome type IV (maps to the ARSG-related atypical Usher phenotype; not part of the classical MONDO USH1/2/3 series)
Inheritance	Autosomal recessive (HP:0000007)
MeSH	Usher Syndromes (D014582) — no dedicated MeSH subheading yet for type IV specifically
ICD-10/11	Falls under H35.5 / Usher syndrome (ICD does not currently subdivide to type IV)

Synonyms / Alternative Names

USH4
Atypical Usher syndrome (the term used in the original 2018 report before "type IV" nomenclature was adopted)
ARSG-related Usher syndrome / ARSG-associated retinitis pigmentosa and hearing loss
Late-onset Usher syndrome (informal)

Nature of Evidence Base

Nearly all available data derive from aggregated case series and case reports (individual patients and families identified through next-generation sequencing in RP/hearing-loss diagnostic cohorts), not large-scale EHR or population-registry data. As of the most recent (2024/2025) cohort expansion, the total published dataset comprises only 31 molecularly confirmed individuals worldwide (Bauwens et al. 2025, PMID:39199020, Clinical Genetics), making USH4 one of the rarest and most recently characterized Usher subtypes. Supporting mechanistic evidence comes from a mouse knockout model and naturally occurring canine disease.

2. Etiology

Disease Causal Factors

USH4 is caused exclusively by biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic pathogenic variants in ARSG, which encodes the lysosomal sulfatase arylsulfatase G. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause — this is a monogenic Mendelian disorder.

Genetic Risk Factors

Causal gene: ARSG (HGNC:24145), chromosome 17q24.2. Pathogenic variants abolish or severely reduce sulfatase enzymatic activity.
Variant spectrum (as of the 2024/2025 cohort of 31 patients across at least 7 publications):
Missense: p.(Asp45Tyr) [founder, Yemenite Jewish], p.(Asp44Asn), p.(Leu92Pro), p.(Arg99His), p.(Pro213Leu), p.(Arg342Trp), p.(Arg384Trp)
Nonsense: p.(Tyr196*)
Frameshift: p.(Thr31Glnfs*9), p.(Gly329Glufs*35), p.(Ser443Alafs*12)
Splice-site: c.1212+1G>A → p.(Val405Ilefs*41); c.1303+5G>T
Large deletions: c.705-3940_982+2952del → p.(Ser235Argfs*29); c.219_454del → p.(Val75*)
(Sources: Khateb 2018; Abad-Morales et al. 2020, PMID:32455177; Peter et al. 2022, PMID:35226187; Bauwens et al. 2025, PMID:39199020)
Founder variants:
p.(Asp45Tyr), homozygous in 5 individuals from 3 Yemenite Jewish families in the original description (Khateb et al. 2018).
c.1150C>T, p.(Arg384Trp) — recurring in 4 of 31 subjects, predominantly of Portuguese origin, suggesting a Portuguese founder allele (Bauwens et al. 2025, PMID:39199020).
Consanguinity: Reported in multiple families, including a Tunisian consanguineous family and the original Yemenite Jewish kindreds — consistent with the very rare, recessive nature of the disease.
No modifier genes or digenic contributions have yet been reported for USH4; unlike some USH2A cases, no oligogenic modulation has been documented.

Environmental Risk Factors

None specifically established for USH4. As with other forms of RP, general age-related and noise-exposure factors that affect hearing broadly could theoretically modulate SNHL severity/progression, but no ARSG-specific gene-environment data exist.

Protective Factors

None reported specific to ARSG or USH4. No protective alleles or environmental protective exposures have been documented in the literature to date.

Gene-Environment Interactions

Not studied for USH4 specifically; the extreme rarity of the condition (n=31 published cases) has precluded epidemiological gene-environment analyses.

3. Phenotypes

USH4 phenotypes fall into two principal domains — retinal and auditory — with vestibular function preserved.

Retinal / Ophthalmologic Phenotypes

Feature	Detail	Suggested HPO term
Rod-cone dystrophy / retinitis pigmentosa	Progressive, later onset than USH1-3; combined scotopic and photopic ERG dysfunction	HP:0000510 (Rod-cone dystrophy)
Ring-shaped/pericentral chorioretinal atrophy	"Ring-shaped retinal atrophy delimiting the vascular arcades temporally and extending beyond the optic nerve nasally, with relative preservation of the mid- and far-periphery"	HP:0007754 (Macular atrophy); HP:0000544 (Chorioretinal atrophy)
Ring scotoma	10–20° visual field ring scotoma	HP:0030518-adjacent (constricted visual fields — HP:0007663 Reduced visual acuity as proxy)
Bone-spicule pigmentation	Intraretinal bone spicules, predominantly nasal/superior to optic disc	HP:0007737 (Bone spicule pigmentation of the retina)
Cystoid macular edema	Present in a subset with preserved outer retinal layers	HP:0045095 (Cystoid macular edema)
Progressive outer retinal layer loss	On OCT	HP:0007906 (Retinal atrophy)
Abnormal fundus autofluorescence	Ring-shaped hyperautofluorescence with mid-peripheral hypoautofluorescence	(no dedicated HPO; document as imaging finding)

Age of onset: Visual symptoms (typically night blindness) reported from 18–65 years, with mean onset in the 4th decade (~40s); one outlier case with symptom onset at age 25 (Bauwens et al. 2025). RP onset overall spans 30–60 years across the combined literature (Peter et al. 2022).

Progression: Progressive; leads to combined ERG extinction (both scotopic and photopic responses eventually absent) and complete loss of outer retinal layers in advanced disease.

Auditory Phenotypes

Feature	Detail	Suggested HPO term
Sensorineural hearing loss	Bilateral, moderate-to-severe, predominantly mid-to-high-frequency, down-sloping audiogram	HP:0000407 (Sensorineural hearing impairment)
Progression rate	~1.0–1.5 dB HL annually (audiometric modeling)	HP:0000505 (progressive hearing loss trait, via clinical_course)
Onset	Self-reported onset from childhood to age 50; calculated audiometric onset ~age 17 in one series, but formal diagnosis/hearing-aid fitting more typically ages 18–67; a later cohort places typical SNHL onset around 40–58 years, generally after visual symptoms	—

Note the striking discrepancy between "calculated" (regression-based) onset age (~17 years) in the Peter et al. cohort versus the later, more typical clinical onset (40s–50s) in the larger Bauwens et al. cohort — reflecting genuine phenotypic heterogeneity and possibly ascertainment/methodology differences between studies.

Vestibular Phenotype

No vestibular involvement reported in the great majority of patients — this is a defining diagnostic feature distinguishing USH4 from USH1–3. One patient in the Bauwens cohort showed incidental "mild cerebral and cerebellar atrophy" on neuroimaging, but no patient has reported clinical vestibular symptoms (vertigo, balance dysfunction, delayed motor milestones). Suggested term: absence of HP:0000501 (Vestibular dysfunction) — i.e., this is a negative finding of diagnostic significance.

Quality of Life Impact

Not formally studied with validated instruments (EQ-5D, SF-36) specific to USH4 in the literature reviewed. By analogy to Usher syndrome broadly, combined progressive dual-sensory (hearing + vision) loss is expected to substantially affect independence, communication, and mobility, though the later onset in USH4 (relative to USH1) may allow patients a longer period of unaffected functioning before intervention becomes necessary.

4. Genetic/Molecular Information

Causal Gene

ARSG (Arylsulfatase G), HGNC gene symbol ARSG, chromosome 17q24.2, OMIM *610008.
Encodes a member of the sulfatase family of lysosomal enzymes.

Variant Classification (ACMG/AMP)

Across the reviewed publications, pathogenicity was established via ACMG/AMP criteria plus functional enzymatic assays: - Missense variants p.(Pro213Leu), p.(Arg384Trp), and p.(Arg99His) were functionally tested and showed "complete loss of sulfatase enzymatic activity" without loss of protein stability (Bauwens et al. 2025, PMID:39199020). - The original founder variant p.(Asp45Tyr) was shown to abolish enzymatic activity in the paper's title itself: "A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans" (Khateb et al. 2018, PMID:29300381). - Missense pathogenic variants also impede correct lysosomal localization, with mutant protein retained aberrantly in the endoplasmic reticulum rather than trafficking to the lysosome.

Variant Type/Class Distribution

Mixed allelic series including missense, nonsense, frameshift, canonical splice-site, and large intragenic deletions — no single dominant mutational mechanism, consistent with a classic loss-of-function recessive disease gene.

Allele Frequency

Individual ARSG pathogenic variants are extremely rare/private in population databases (gnomAD), consistent with the extreme rarity of the phenotype (only 31 published cases worldwide); the two founder alleles (Yemenite Jewish p.Asp45Tyr; presumptive Portuguese p.Arg384Trp) are expected to show population-specific enrichment but specific gnomAD allele counts were not available from the sources reviewed here and should be verified directly in gnomAD/ClinVar before curation.

Somatic vs. Germline

Exclusively germline — USH4 is a classic Mendelian recessive disorder with no somatic/mosaic mechanism reported.

Functional Consequences

Loss of function — pathogenic ARSG variants abolish sulfatase catalytic activity and, for at least some missense alleles, cause ER retention/mistrafficking rather than proper lysosomal delivery, representing a combined catalytic-loss + trafficking-defect mechanism.

Modifier Genes

None reported.

Epigenetic Information

No epigenetic (DNA methylation, histone) data specific to ARSG/USH4 were identified in the literature reviewed.

Chromosomal Abnormalities

No aneuploidy, translocation, or large structural chromosomal rearrangements reported as a cause of USH4; the largest documented lesion is an intragenic multi-exon deletion (c.705-3940_982+2952del).

5. Environmental Information

No environmental, occupational, lifestyle, or infectious causal/risk factors have been documented for USH4 specifically in the literature. As a purely monogenic recessive disorder, environmental contribution to primary disease causation is not established. (General environmental modifiers of hearing loss and RP progression that apply across all forms of these sensory disorders — e.g., noise exposure, UV exposure — have not been specifically studied in the ARSG-USH4 context.)

6. Mechanism / Pathophysiology

Molecular Function of ARSG

ARSG encodes a lysosomal sulfatase ("arylsulfatase G") that functions in the stepwise lysosomal degradation of heparan sulfate, specifically removing terminal N-sulfoglucosamine-3-O-sulfate residues from the non-reducing end of heparan sulfate chains (OMIM *610008; GeneCards ARSG summary).

Tissue/Cellular Localization

In the mouse retina, ARSG protein expression is restricted to the retinal pigment epithelium (RPE) — it is not detectably expressed in photoreceptors themselves. Heparan sulfate proteoglycans are components of the interphotoreceptor matrix that must be turned over by RPE lysosomal machinery (Kruszewski et al. 2016, IOVS, PMID:26975023).

Proposed Causal Chain (Retina)

Trigger: Biallelic ARSG loss-of-function variants → loss of arylsulfatase G catalytic activity in RPE lysosomes.
Molecular consequence: Failure to degrade terminal sulfated heparan sulfate residues → accumulation of undegraded heparan sulfate proteoglycans within RPE phagolysosomes.
Secondary consequence: Because RPE lysosomes also process phagocytosed photoreceptor outer-segment material daily, storage-material accumulation is proposed to secondarily impair RPE handling of photoreceptor outer segment components, including recycling/delivery of the visual chromophore 11-cis-retinal back to photoreceptors — a function essential for the visual (retinoid) cycle.
Cellular consequence: Impaired RPE support function → progressive photoreceptor cell death, with reactive astrogliosis and microgliosis (evident in outer but not inner retina) as downstream inflammatory/reactive changes, and elevated expression of other lysosomal proteins as a compensatory/stress response (Kruszewski et al. 2016, PMID:26975023).
Clinical consequence: Progressive rod-cone dystrophy with the ring/pericentral atrophy pattern characteristic of USH4.

This is mechanistically analogous to other lysosomal storage disease paradigms (heparan sulfate is also the accumulating substrate in Mucopolysaccharidosis III/Sanfilippo syndrome, which is caused by defects in other heparan-sulfate-degrading sulfatases/enzymes), positioning USH4 within the broader lysosomal substrate-accumulation disease-mechanism class.

Mechanism in the Cochlea

The precise cochlear cell-autonomous mechanism of ARSG-related hearing loss is less well characterized experimentally than the retinal mechanism, but by analogy is presumed to involve heparan sulfate proteoglycan accumulation in inner-ear supporting/epithelial cells impairing normal cochlear homeostasis and hair-cell/spiral-ganglion function, producing progressive high-frequency sensorineural hearing loss.

Cell Types Involved

Retinal pigment epithelial cell (site of primary ARSG deficiency) — suggested CL term: CL:0002586 (retinal pigment epithelial cell)
Photoreceptor cell (rod and cone; site of secondary degeneration) — CL:0000210 (photoreceptor cell); CL:0000604 (retinal rod cell); CL:0000573 (retinal cone cell)
Cochlear hair cells / spiral ganglion neurons (presumed site of auditory pathology, not directly demonstrated) — CL:0000601 (auditory hair cell); CL:0000392 (spiral ganglion neuron, if applicable)
Astrocytes and microglia (reactive gliosis in the outer retina) — CL:0000127 (astrocyte); CL:0000129 (microglial cell)

Suggested GO Terms

GO:0008484 (sulfuric ester hydrolase activity) — molecular function of ARSG
GO:0030201 (heparan sulfate proteoglycan metabolic process)
GO:0030203 (glycosaminoglycan metabolic process)
GO:0007601 (visual perception)
GO:0016185 (synaptic vesicle within endosome — not directly relevant)
GO:0034381 (plasma lipoprotein particle clearance — not relevant)
GO:0007605 (sensory perception of sound)
GO:0034976 (response to endoplasmic reticulum stress) — relevant given ER-retention mechanism of some missense alleles

Molecular Profiling / Omics

No transcriptomic, proteomic, or single-cell datasets specific to human USH4/ARSG-deficient tissue were identified in the literature search. The mouse knockout model (below) provides tissue-level histopathology but not published omics datasets in the sources reviewed.

7. Anatomical Structures Affected

Organ Level

Primary organs: Eye (retina) and ear (cochlea/inner ear)
Body systems: Visual system and auditory system; no vestibular system involvement (a key negative finding); no other organ systems are affected in isolated USH4 (unlike the canine ARSG phenotype, which involves broader CNS/cerebellar disease — see Section 14).
Suggested UBERON terms: UBERON:0000966 (retina), UBERON:0001690 (ear), UBERON:0002104 (retinal pigment epithelium), UBERON:0001846 (organ of Corti — cochlear structure)

Tissue and Cell Level

Retinal pigment epithelium — primary site of ARSG expression and enzymatic deficiency.
Neural retina (photoreceptor layer, particularly outer segments) — site of secondary degeneration.
Cochlear sensory epithelium — presumed site of auditory pathology (not directly demonstrated histologically in humans).

Subcellular Level

Lysosome — the organelle where ARSG normally functions and where undegraded substrate accumulates (GO Cellular Component: GO:0005764, lysosome; GO:0005775, vacuolar lumen).
Endoplasmic reticulum — site of aberrant retention of mistrafficked mutant ARSG protein for at least some missense alleles (GO:0005783, endoplasmic reticulum).

Localization

Retina: Ring-shaped/pericentral pattern of atrophy around the vascular arcades and macula, with relative sparing of mid- and far-periphery — a distinctive localization pattern that differentiates USH4 from the more diffuse peripheral-to-central RP typical of USH1/2.
Ear: Bilateral hearing loss (no reported unilateral/asymmetric cases); no vestibular (semicircular canal/otolith) involvement.

8. Temporal Development

Onset

Visual (RP) onset: 18–65 years, mean ~40s; markedly later than USH1 (congenital-severe), USH2 (congenital-moderate hearing loss, RP onset childhood/adolescence), and USH3 (progressive childhood-onset hearing loss).
Auditory onset: Variably reported 40–58 years in the larger recent cohort, though earlier studies calculated an audiometric onset around age 17 based on regression modeling; clinical recognition (hearing aid fitting) more typically occurs ages 18–67.
Pattern: Insidious, gradual onset for both modalities — not acute or episodic.

Progression

Retinal: Progressive rod-cone degeneration; combined scotopic/photopic ERG dysfunction progressing over years to complete extinguishment; progressive loss of outer retinal layers on OCT; eventual severe visual field constriction.
Auditory: Progressive SNHL, estimated at ~1.0–1.5 dB HL/year based on audiometric modeling in one study.
Course: Chronic, progressive, non-remitting; no episodic or relapsing-remitting pattern reported.
Duration: Lifelong, chronic condition with no spontaneous remission.

Patterns

No remission patterns reported (progressive disorder).
Critical/intervention windows are not formally defined for USH4 but, by analogy to RP generally, earlier diagnosis enables earlier low-vision/hearing rehabilitation and genetic counseling before profound sensory loss develops.

9. Inheritance and Population

Epidemiology

USH4 is exceptionally rare: only 31 molecularly confirmed patients have been published as of the most recent (2024/2025) cohort expansion (Bauwens et al. 2025, PMID:39199020), up from an initial report of 5 patients in 2018 and small subsequent case series/reports.
For comparison, Usher syndrome overall has an estimated prevalence of ~1/10,000 (Delmaghani & El-Amraoui 2022, PMID:35353227) to 4–17 per 100,000 people; USH4 represents a very small fraction of this total, reflecting either genuine rarity or under-ascertainment (given its late onset, USH4 patients may be diagnosed as isolated late-onset RP or presbycusis-like hearing loss rather than recognized as syndromic Usher disease).
No formal incidence, birth-prevalence, or carrier-frequency estimates specific to ARSG/USH4 were identified.

Inheritance Pattern

Autosomal recessive — all reported cases are homozygous or compound heterozygous for ARSG pathogenic variants.
Penetrance: Appears complete among biallelic carriers reported to date, though ascertainment bias (patients identified through symptomatic diagnostic sequencing) limits confidence in this conclusion.
Expressivity: Variable — age of onset for both hearing loss and RP varies substantially between patients (visual onset 18–65 years; hearing loss onset childhood–50s by self-report), and phenotype severity (e.g., presence/absence of cystoid macular edema, degree of hearing loss) also varies.
Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).
Germline mosaicism: Not specifically reported.
Founder effects: Documented — Yemenite Jewish founder variant p.(Asp45Tyr); likely Portuguese founder variant p.(Arg384Trp).
Consanguinity: Reported in several of the founding/index families (Yemenite Jewish kindreds, a Tunisian family).
Carrier frequency: Not established in the literature reviewed; would require dedicated population screening or gnomAD analysis of specific ARSG alleles.

Population Demographics

Affected populations: Cases reported from Israel (Yemenite Jewish), Spain, Belgium, France, Portugal, USA, and Tunisia — a geographically and ethnically diverse but numerically very small set of families.
Geographic distribution: Portugal appears disproportionately represented (9 of 31 total published subjects, including a likely founder allele), suggesting a possible regional enrichment, though this could also reflect ascertainment bias from strong Portuguese ophthalmogenetics research programs.
Sex ratio: Not specifically reported as skewed; consistent with autosomal (not X-linked) recessive inheritance, no sex predilection is expected.
Age distribution: All published cases are adults (given the late-onset nature of the disease by definition); no pediatric-onset cases have been reported.

10. Diagnostics

Clinical Tests

Fundus examination: Ring-shaped/pericentral retinal atrophy pattern around the vascular arcades, extending nasally beyond the optic disc; intraretinal bone-spicule pigmentation predominantly nasal and superior to the disc.
Optical coherence tomography (OCT): Progressive loss of outer retinal layers, variably with cystoid macular edema.
Fundus autofluorescence (FAF): Ring-shaped hyperautofluorescence with hypoautofluorescence in the mid-periphery.
Full-field electroretinogram (ERG): Combined scotopic and photopic dysfunction, progressing to extinguished responses in advanced disease.
Visual field testing: Ring scotoma (10–20°).
Pure-tone audiometry: Bilateral, predominantly mid-to-high-frequency, down-sloping sensorineural hearing loss.
Vestibular testing: Performed to document the absence of vestibular dysfunction, a key differentiating feature from USH1–3 — important for the differential diagnostic workup.

Genetic Testing

Recommended approach: Given the phenotypic overlap with non-syndromic late-onset RP and with age-related hearing loss, molecular diagnosis of USH4 typically occurs via targeted RP/inherited retinal disease gene panels or hearing-loss gene panels that include ARSG, or via whole-exome sequencing (WES) in cases where syndromic Usher disease is suspected but standard USH1/2/3 gene panels (MYO7A, USH2A, CDH23, PCDH15, CLRN1, etc.) are negative.
Confirmatory functional testing: Given the relatively recent characterization of ARSG as a disease gene and the predominance of novel/private missense variants (many classified only as "likely pathogenic" on ACMG criteria alone), enzymatic sulfatase activity assays have been used in multiple studies to confirm variant pathogenicity — an important diagnostic adjunct beyond standard variant classification.
Chromosomal microarray / karyotyping: Not indicated — no reported CNV or chromosomal mechanism beyond the single reported large intragenic deletion.

Clinical Diagnostic Criteria

Proposed diagnostic criteria for USH4 based on Peter et al. 2022 (PMID:35226187): | Feature | USH4 characteristic | |---|---| | Hearing loss | Moderate-to-severe SNHL, later onset than USH1-3 | | Visual impairment | RP onset 30–65 years; pericentral/macular ring-atrophy pattern | | Vestibular function | Normal (no reported dysfunction) | | Genetic basis | Biallelic ARSG variants with loss of sulfatase activity |

Differential Diagnosis

Non-syndromic autosomal recessive RP (without hearing loss)
Usher syndrome types 1–3 (distinguished by earlier onset, presence/degree of vestibular dysfunction, and different causal genes: MYO7A/USH1C/CDH23/PCDH15/USH1G for USH1; USH2A/ADGRV1/WHRN for USH2; CLRN1 for USH3)
Age-related macular degeneration and presbycusis (when onset is very late and family history is not apparent — a plausible source of underdiagnosis)
Other syndromic retinal-hearing disorders (e.g., Alström syndrome, though this carries additional systemic features)

Screening

No population-based newborn or carrier screening programs specific to ARSG/USH4 exist, consistent with its extreme rarity and late age of onset (which makes newborn screening for this specific indication low-yield).

11. Outcome/Prognosis

Survival and Mortality

USH4 is not associated with reduced life expectancy or increased mortality — it is a purely sensory (visual + auditory), non-life-threatening disorder. No survival/mortality data specific to USH4 were identified (or would be expected) in the literature, consistent with this being a quality-of-life/functional disorder rather than a lethal one.

Morbidity and Function

Progressive dual sensory impairment, ultimately combining significant visual field constriction/central vision loss with moderate-to-severe hearing loss.
Because onset is later in life than other Usher types, patients typically have a substantial period of normal or near-normal sensory function before disease manifests, which may lessen the developmental/educational impact seen in congenital forms (USH1) but still poses major challenges to independence, driving, and communication in mid-to-late adulthood.
No formal quality-of-life instrument data (EQ-5D, SF-36) specific to USH4 were found.

Disease Course

Complications: Progressive visual field constriction to legal blindness is expected in advanced RP (by analogy with other RP-causing genes); cystoid macular edema, when present, can cause additional acute-on-chronic visual decline.
Recovery potential: None — as a progressive degenerative disorder, spontaneous recovery is not expected; symptomatic/supportive management (below) aims to slow progression and support residual function rather than reverse disease.

Prognostic Factors

Specific genotype-phenotype correlations remain incompletely established given the small cohort size, though functionally "null" variants (nonsense, frameshift, large deletions) might be expected to correlate with earlier/more severe disease compared with hypomorphic missense alleles — this has not been rigorously demonstrated in the literature reviewed and should be treated as a hypothesis rather than an established finding.
No validated prognostic biomarkers specific to ARSG/USH4 have been reported.

12. Treatment

There is no disease-specific, FDA-approved, or ARSG-targeted therapy for USH4. Management is supportive/symptomatic, following the general Usher syndrome treatment paradigm:

Pharmacotherapy

High-dose vitamin A palmitate: A long-term NEI/Foundation Fighting Blindness-supported clinical trial in RP patients broadly (not USH4-specific) showed vitamin A may modestly slow RP progression, though it does not halt or cure it. Applicability to ARSG-specific RP has not been separately studied.
No ARSG-targeted small-molecule or enzyme-replacement therapy currently exists (unlike some other lysosomal disorders), though the lysosomal storage mechanism (heparan sulfate accumulation) is conceptually analogous to diseases where enzyme replacement or substrate reduction therapy has been explored (e.g., MPS disorders) — this remains speculative for USH4 and not clinically established.
NCIT term: NCIT:C15986 (Pharmacotherapy) as the generic treatment_term for vitamin A supplementation, with therapeutic_agent bound to retinol/vitamin A (CHEBI).

Advanced/Experimental Therapeutics

Gene therapy: Broadly under investigation for Usher syndrome (multiple USH1/USH2 gene-specific programs, e.g., AAV-based approaches, antisense oligonucleotide exon-skipping for USH2A), but no ARSG-specific gene therapy program has been identified in the literature/trial registries reviewed. Given ARSG's relatively large coding sequence and the loss-of-function mechanism, AAV-based gene augmentation (as pursued for other recessive LOF retinal disease genes) would be a plausible future therapeutic direction but is not yet in development based on available sources. NCIT:C15238 (Gene Therapy).
RNA-based therapies: Antisense oligonucleotide and RNA-editing approaches are in development for other Usher genes (particularly USH2A); not reported for ARSG.
No cell-based or CRISPR gene-editing therapies specific to USH4 were identified.

Hearing Management

Hearing aids: First-line for the moderate-to-severe SNHL of USH4, given the later onset and progressive (rather than profound congenital) nature of the hearing loss — contrasting with USH1, where cochlear implantation is often needed early due to profound congenital deafness.
Cochlear implantation: A reasonable option later in the disease course if hearing aids become insufficient, as used in USH2/USH3.
Assistive listening devices, speech therapy as needed.
NCIT term: no dedicated device term for hearing aids in NCIT; cochlear implantation may map to a device/procedure NCIT term where applicable.

Vision Support

Low-vision rehabilitation services, orientation and mobility training, optical/electronic low-vision aids — NCIT:C15315 (Rehabilitation).
Genetic counseling for patients and at-risk relatives given autosomal recessive inheritance — NCIT:C15240 (Genetic Counseling).

Treatment Outcomes

No systematic treatment-response, adverse-event, or comparative-effectiveness data specific to USH4 patients were identified — reflecting both the rarity of the condition and the absence of disease-specific interventional trials.

Treatment Strategy

Management is currently symptomatic and multidisciplinary (ophthalmology, audiology, genetics, low-vision/hearing rehabilitation services), following general Usher syndrome clinical practice guidelines rather than an USH4-specific treatment algorithm. No combination or genotype-guided precision therapy currently exists for this gene.

13. Prevention

Prevention Levels

Primary prevention: Not applicable in the traditional sense (no modifiable risk-factor avoidance can prevent a monogenic recessive disorder); the relevant "primary prevention" tool is reproductive genetic counseling and carrier screening in at-risk families/populations (e.g., relatives of Yemenite Jewish or Portuguese founder-variant carriers), including preimplantation genetic diagnosis (PGD) or prenatal testing for at-risk couples.
Secondary prevention: Early molecular diagnosis (via genetic testing in patients presenting with combined late-onset RP + hearing loss, even without classic vestibular Usher features) allows earlier initiation of low-vision and hearing rehabilitation before profound impairment develops.
Tertiary prevention: Standard RP/hearing-loss complication management (as above) to preserve function and quality of life once disease is established.

Immunization

Not applicable — USH4 has no infectious etiology.

Screening and Early Detection

No population-based newborn screening program exists (or would be expected, given the late-onset nature).
Carrier screening / genetic counseling is the most relevant preventive tool, particularly in populations with known founder alleles (Yemenite Jewish community for p.Asp45Tyr).
Cascade genetic testing of at-risk siblings/relatives of an index USH4 patient is appropriate given autosomal recessive inheritance and the substantial reproductive-planning implications.

Behavioral Interventions

No specific behavioral/lifestyle interventions have been shown to prevent or delay ARSG-related disease onset.

Public Health / Environmental Interventions

Not applicable — no environmental exposure has been implicated in causation.

Prophylaxis

No prophylactic medications or procedures are established for at-risk (biallelic, presymptomatic) individuals.

14. Other Species / Natural Disease

Mouse (Mus musculus, NCBITaxon:10090)

Arsg knockout (Arsg−/−) mice recapitulate key features of the human retinal phenotype: progressive photoreceptor degeneration beginning between 1–6 months of age, with >50% photoreceptor loss by 24 months, accompanied by reactive astrogliosis, outer-retina-predominant microgliosis, and elevated lysosomal protein expression (Kruszewski et al. 2016, IOVS, PMID:26975023). This model strongly supports RPE-lysosomal-storage as the retinal disease mechanism (see Section 6) and represents a high-fidelity model for the retinal component of USH4, though the paper does not report on auditory phenotyping of this line in the sources reviewed here.
Orthologous gene: Mouse Arsg (MGI ortholog of human ARSG).

Dog (Canis lupus familiaris, NCBITaxon:9615)

American Staffordshire Terriers (and related American Pit Bull Terriers) carry a naturally occurring ARSG missense variant (c.296G>A, p.Arg99His) causing a late-onset, adult-onset neuronal ceroid lipofuscinosis (NCL)-like neurodegenerative disorder with progressive ataxia and thalamocerebellar neuronal storage of ceroid lipopigment, typically presenting between 3–6 years of age (Abitbol et al. 2010, PNAS, PMID:20679209).
Notably, the identical p.(Arg99His) variant has since been reported in a human USH4 patient (homozygous in one subject, heterozygous in another, in the Bauwens et al. 2025 cohort), who presented with the isolated USH ocular/auditory phenotype without the broader neurological (ataxic/cerebellar) manifestations seen in the canine disease — an important cross-species phenotype divergence worth flagging as a HUMAN_MODEL_MISMATCH-type consideration: the same variant produces a primarily CNS/neurodegenerative storage disease in dogs but an apparently CNS-sparing, sensory-restricted (retina + cochlea) phenotype in the one human case reported to carry it.
A more recent study additionally examined retinal function deficits in American Staffordshire Terriers with this late-onset ARSG-associated neurodegenerative disease, providing further cross-species retinal phenotyping data (2024–2025 publication; PubMed ID referenced as 41295716 in search results — confirm directly before citing, as this ID was not independently verified via full-text retrieval in this session).
Veterinary relevance: ARSG-NCL is used as a breed-health genetic test in American Staffordshire Terriers (commercial panels available), demonstrating direct veterinary clinical importance beyond its comparative-biology value.

Comparative Biology

The dog and mouse models together support a conserved role for ARSG in lysosomal heparan sulfate catabolism across mammals, with tissue-specific consequences of loss of function (retina/RPE-restricted degeneration in mouse and the isolated human USH4 case vs. broader CNS/thalamocerebellar storage disease in the canine NCL phenotype) — suggesting that the precise clinical presentation of ARSG deficiency may depend on additional genetic background, allele-specific residual activity, and/or species-specific tissue distribution of ARSG expression and heparan sulfate substrate turnover requirements.

Transmission

Not applicable — ARSG deficiency is a genetic, non-infectious, non-zoonotic condition; there is no cross-species transmission risk (the human and canine diseases are independently occurring genetic disorders of the orthologous gene, not a transmissible disease).

15. Model Organisms

Model	Type	Genetic modification	Phenotype recapitulation	Key reference
*Mouse (Arsg−/−)*	Mammalian, genetic knockout	Constitutive Arsg knockout	High fidelity for the retinal component: progressive photoreceptor degeneration, reactive gliosis, lysosomal storage — closely mirrors the RPE-driven degenerative mechanism proposed for human USH4 retinal disease	Kruszewski et al. 2016, PMID:26975023
Dog (American Staffordshire Terrier, naturally occurring ARSG p.R99H)	Mammalian, naturally occurring (induced-in-nature) genetic model	Spontaneous homozygous missense variant	Partial/divergent recapitulation: reproduces lysosomal ceroid storage and neurodegeneration, but with a broader CNS/cerebellar-ataxic phenotype not seen in the one human carrier of the same variant reported to date — a valuable but imperfect cross-species model, useful for studying ARSG biology and neuronal storage pathology but requiring caution when extrapolating CNS findings to human USH4	Abitbol et al. 2010, PMID:20679209

Model Limitations

Neither model has been reported (in the sources reviewed) to comprehensively recapitulate the auditory (cochlear) component of human USH4 — the mouse study focused on retinal histopathology, and the canine model's primary described phenotype is CNS/cerebellar rather than cochlear. This represents a notable gap: the cochlear/auditory cell-autonomous mechanism of ARSG deficiency remains largely uncharacterized at the animal-model level based on available literature.
No iPSC-derived, organoid, or other non-animal (NAM) model system for ARSG deficiency (e.g., retinal organoid or inner-ear organoid) was identified in this search — representing an opportunity for future human-cell model development.
No CRISPR knockout/knock-in cell-line screens or DepMap-type functional genomics data specific to ARSG were identified.

Research Applications

The mouse Arsg−/− model is well-suited for studying the RPE-lysosomal-storage mechanism of retinal degeneration and could support preclinical testing of substrate-reduction or enzyme-replacement strategies; the canine model offers a naturally occurring, genetically homogeneous (breed-associated) system for studying ARSG-related neuronal storage pathology and could be valuable for comparative therapeutic (e.g., gene therapy) proof-of-concept studies given the tractability of companion-animal clinical trials.

Summary of Key Ontology Term Suggestions

Category	Suggested terms
Disease	MONDO (ARSG-related Usher syndrome type IV — verify exact MONDO ID before curation); OMIM:618144
Causal gene	hgnc: ARSG (verify HGNC numeric ID directly — not independently confirmed in this session)
Phenotypes (HP)	HP:0000510 (Rod-cone dystrophy), HP:0007754 (Macular atrophy), HP:0000544 (Chorioretinal atrophy), HP:0007737 (Bone spicule pigmentation of the retina), HP:0045095 (Cystoid macular edema), HP:0000407 (Sensorineural hearing impairment), HP:0000007 (Autosomal recessive inheritance)
Biological processes (GO)	GO:0008484 (sulfuric ester hydrolase activity), GO:0030201 (heparan sulfate proteoglycan metabolic process), GO:0007601 (visual perception), GO:0007605 (sensory perception of sound)
Cell types (CL)	CL:0002586 (retinal pigment epithelial cell), CL:0000210 (photoreceptor cell), CL:0000604 (retinal rod cell), CL:0000573 (retinal cone cell), CL:0000127 (astrocyte), CL:0000129 (microglial cell)
Anatomy (UBERON)	UBERON:0000966 (retina), UBERON:0002104 (retinal pigment epithelium), UBERON:0001690 (ear), UBERON:0001846 (organ of Corti)
Treatment (NCIT)	NCIT:C15986 (Pharmacotherapy — vitamin A), NCIT:C15315 (Rehabilitation — low vision/hearing), NCIT:C15240 (Genetic Counseling), NCIT:C15238 (Gene Therapy — investigational, not USH4-specific)

Key Evidence Gaps and Caveats for Curation

Small evidence base: Only 31 published patients worldwide — every clinical parameter (onset ages, progression rates, penetrance) carries wide confidence intervals and should be curated with appropriate FrequencyEnum caution rather than presented as fixed values.
Discrepant hearing-loss onset estimates between the 2022 (calculated ~age 17) and 2024/2025 (typical 40–58 years) cohorts — flag as an open question rather than reconciling artificially.
Cross-species model mismatch: the canine ARSG p.R99H variant causes a CNS/cerebellar-predominant NCL phenotype, while the same variant in the one reported human carrier causes an isolated sensory (USH4) phenotype without neurological involvement — a genuine HUMAN_MODEL_MISMATCH worth flagging explicitly.
No auditory-specific animal model has been reported; the mechanistic chain for cochlear pathology is inferred by analogy to the retinal mechanism, not directly demonstrated.
Several ORPHA/ClinVar/gnomAD-specific data points (exact ORPHA code, precise allele frequencies) could not be independently confirmed via full-text retrieval in this session (OMIM and PubMed pages returned access-restricted/cookie-blocked responses) and should be verified directly against OMIM #618144, ClinVar, and gnomAD before final curation.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	11
Resolved	11
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	11
On topic	10
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Usher Syndrome Type 4 (USH4): Comprehensive Research Report

1. Disease Information

Overview

Key Identifiers

Synonyms / Alternative Names

Nature of Evidence Base

2. Etiology

Disease Causal Factors

Genetic Risk Factors

Environmental Risk Factors

Protective Factors

Gene-Environment Interactions

3. Phenotypes

Retinal / Ophthalmologic Phenotypes

Auditory Phenotypes

Vestibular Phenotype

Quality of Life Impact

4. Genetic/Molecular Information

Causal Gene

Variant Classification (ACMG/AMP)

Variant Type/Class Distribution

Allele Frequency

Somatic vs. Germline

Functional Consequences

Modifier Genes

Epigenetic Information

Chromosomal Abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

Molecular Function of ARSG

Tissue/Cellular Localization

Proposed Causal Chain (Retina)

Mechanism in the Cochlea

Cell Types Involved

Suggested GO Terms

Molecular Profiling / Omics

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

Localization

8. Temporal Development

Onset

Progression

Patterns

9. Inheritance and Population

Epidemiology

Inheritance Pattern

Population Demographics

10. Diagnostics

Clinical Tests

Genetic Testing

Clinical Diagnostic Criteria

Differential Diagnosis

Screening

11. Outcome/Prognosis

Survival and Mortality

Morbidity and Function

Disease Course

Prognostic Factors

12. Treatment

Pharmacotherapy

Advanced/Experimental Therapeutics

Hearing Management